Role of functional imaging in the management of lymphoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.32.5225PMID 21482982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

  2011cited by this paper
• Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

  2011cited by this paper
• Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD.

  2010cited by this paper
• Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy.

  2010cited by this paper
• Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

  2010cited by this paper
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

  2010cited by this paper
• Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

  2010cited by this paper
• Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.

  2010cited by this paper
• Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study.

  2010cited by this paper
• 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma

  2010cited by this paper
• Surveillance imaging of Hodgkin lymphoma patients in first remission

  2010cited by this paper
• Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

  2010cited by this paper
• Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy

  2010cited by this paper
• 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

  2010cited by this paper
• Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

  2010cited by this paper
• The sarcoid-lymphoma syndrome.

  2010cited by this paper
• Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

  2010cited by this paper
• Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

  2010cited by this paper
• Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

  2010cited by this paper
• Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.

  2009cited by this paper
• The case against heavy PETing.

  2009cited by this paper
• Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation.

  2009cited by this paper
• Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

  2009cited by this paper
• Report on the First International Workshop on interim-PET scan in lymphoma

  2009cited by this paper
• FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.

  2009cited by this paper
• Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.

  2009cited by this paper
• Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

  2009cited by this paper
• PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

  2009cited by this paper
• Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

  2009cited by this paper
• Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

  2009cited by this paper
• Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

  2009cited by this paper
• Persistence of donor-derived protein in host myeloid cells after induced rejection of engrafted allogeneic bone marrow cells.

  2009cited by this paper
• High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

  2009cited by this paper
• Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

  2009cited by this paper
• Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL)

  2008cited by this paper
• Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

  2008cited by this paper
• Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma

  2008cited by this paper
• Wilms’ Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection

  2008cited by this paper
• Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.

  2008cited by this paper
• Platelets Having a W127X Mutation in GPIX Express Sufficient Residual Amounts of the GPIbα Chain to Support Ristocetin-Mediated Agglutination and Adhesion to VWF and Collagen Under Conditions of Flow.

  2008cited by this paper
• The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

  2008cited by this paper
• The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.

  2007cited by this paper
• Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

  2007cited by this paper
• Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

  2007cited by this paper
• FDG-PET in T-cell and NK-cell neoplasms.

  2007cited by this paper
• Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

  2007cited by this paper
• Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

  2007cited by this paper
• Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

  2006cited by this paper
• Follicular lymphoma international prognostic index

  2006cited by this paper
• Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

  2006cited by this paper
• PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

  2006cited by this paper
• The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

  2006cited by this paper
• Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation

  2006cited by this paper
• FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease

  2006cited by this paper
• Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

  2006cited by this paper
• Association of estrogen receptor-alpha genepolymorphisms with venous thrombosis.

  2006cited by this paper
• 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.

  2006cited by this paper
• Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease

  2006cited by this paper
• Molecular imaging of proliferation in malignant lymphoma.

  2006cited by this paper
• Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

  2006cited by this paper
• 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference.

  2006cited by this paper
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

  2006cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

  2005cited by this paper
• FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases.

  2005cited by this paper
• FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

  2005cited by this paper
• Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

  2005cited by this paper
• [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

  2005cited by this paper
• Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.

  2005cited by this paper
• Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651

  2005cited by this paper
• 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

  2005cited by this paper
• Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation

  2005cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease.

  2004cited by this paper
• Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

  2004cited by this paper
• Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases.

  2003cited by this paper
• Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

  2003cited by this paper
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

  2003cited by this paper
• Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.

  2003cited by this paper
• Utility of FDG-PET scanning in lymphoma by WHO classification.

  2003cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

  2002cited by this paper
• Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma

  2002cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

  2002cited by this paper
• Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

  2002cited by this paper
• Thallium‐201 Imaging in Evaluation of Hodgkin's Disease

  2002cited by this paper
• 2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

  2001cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

  2001cited by this paper
• Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

  2001cited by this paper
• Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

  2001cited by this paper
• Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

  2001cited by this paper
• Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

  2001cited by this paper
• Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma

  2001cited by this paper
• 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.

  2000cited by this paper

• A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.

  2026cites this paper
• The prognostic value of metabolic heterogeneity parameter coefficient of variation (COV) of baseline 18F-FDG PET/CT in newly diagnosed diffuse large B-cell lymphoma.

  2026cites this paper
• Patients with follicular lymphoma should be treated according to baseline PET-CT findings with targeted re-biopsy

  2025cites this paper
• Imaging findings for 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in blastic plasmacytoid dendritic cell neoplasm: case series and literature review

  2025cites this paper
• Recent Advances and Challenges in Cancer Care, with a Focus on Multiple Myeloma, Lymphoma, and Lung Cancer: Key Insights from the Onco Summit 2024-The APAC Chapter

  2025cites this paper
• Postoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?

  2025cites this paper
• Comparison of different response evaluation criteria in interim PET/computed tomography for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?

  2025cites this paper
• Efficacy of PR2-based immunotherapy in the treatment of diffuse large B-cell lymphoma-associated neurolymphomatosis: A report on two cases

  2025cites this paper
• Hodgkin lymphoma and liquid biopsy: a story to be told

  2024cites this paper
• Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

  2024cites this paper
• B-cell non-Hodgkin lymphomas.

  2024cites this paper
• Dual-Layer Spectral Detector Computed Tomography Quantitative Parameters: A Potential Tool for Lymph Node Activity Determination in Lymphoma Patients

  2024cites this paper
• Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma

  2023cites this paper
• Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

  2023cites this paper
• Nuclear medicine techniques in paediatric body oncology: Present and future

  2023cites this paper
• Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma

  2023cites this paper
• Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome

  2023cites this paper
• Prediction nomogram based on 18F-FDG PET/CT and clinical parameters for patients with diffuse large B-cell lymphoma

  2023cites this paper
• Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography

  2023cites this paper
• FDG-PET in Relapsed/Refractory Hodgkin Lymphoma: a practical approach.

  2023cites this paper
• Case Report: Skeletal Muscle Lymphoma as a Result of Slow Centrifugal Migration of Untreated Primary Neurolymphomatosis?

  2022cites this paper
• Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study

  2022cites this paper
• Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018

  2022cites this paper
• PET imaging of hematological neoplasia

  2022cites this paper
• Multimodal deep learning model on interim [^18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma

  2022cites this paper
• Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.

  2022cites this paper
• Automatic classification of lymphoma lesions in FDG-PET–Differentiation between tumor and non-tumor uptake

  2022cites this paper
• Molecular Imaging of Lymphoma: Future Directions and Perspectives.

  2022cites this paper
• PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies

  2022cites this paper
• Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT

  2022cites this paper
• The diagnosis and management of suspected lymphoma in general practice

  2022cites this paper
• Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas.

  2021cites this paper
• FDG-PET/CT in Lymphoma: Where Do We Go Now?

  2021cites this paper
• FDG PET/CT findings and post-treatment changes of COVID-19 pneumonia in a patient with lymphoma: A case report.

  2021cites this paper
• Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.

  2021cites this paper
• End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.

  2021cites this paper
• Dynamic evaluation of the prognostic value of 18F-FDG PET/CT in extranodal NK/T-cell lymphoma, nasal type

  2021cites this paper
• PET imaging of lymphomas

  2021cites this paper
• Prognostic Indicators of Survival in Sinonasal Diffuse Large B‐Cell Lymphoma: A National Cancer Database Analysis

  2021cites this paper
• PET CT in Non-Hodgkin Lymphoma

  2021cites this paper
• Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients

  2021cites this paper
• High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse

  2021cites this paper
• Uncommon Variants of Mature T-Cell Lymphomas (MTCLs): Imaging and Histopathologic and Clinical Features with Updates from the Fourth Edition of the World Health Organization (WHO) Classification of Lymphoid Neoplasms

  2021cites this paper
• Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

  2021cites this paper
• Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions

  2021cites this paper
• Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin’s lymphoma

  2021cites this paper
• Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma

  2021cites this paper
• Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.

  2021cites this paper
• Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma

  2021cites this paper
• Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.

  2020cites this paper
• YAYGIN BÜYÜK B HÜCRELİ LENFOMA (YBBHL) TANILI OLGULARIN RETROSPEKTİF DEĞERLENDİRMESİ

  2020cites this paper
• Bildgebende Diagnostik von malignen Lymphomen*

  2020cites this paper
• Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT.

  2020cites this paper
• Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols

  2020cites this paper
• The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas

  2020cites this paper
• Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Resolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post‐transplant cyclophosphamide in adult T‐cell leukemia/lymphoma

  2020cites this paper
• Case Study: Management of a patient with Primary Mediastinal B-cell Lymphoma (PMBL)

  2020cites this paper
• Diagnostic approach in hepatic lymphoma: radiological imaging findings and literature review

  2020cites this paper
• Bildgebende Diagnostik von malignen Lymphomen

  2020cites this paper
• Coarse-to-Fine Adversarial Networks and Zone-Based Uncertainty Analysis for NK/T-Cell Lymphoma Segmentation in CT/PET Images

  2020cites this paper
• Update on Hodgkin lymphoma from a radiologist's perspective.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hodgkin Lymphoma, Version 2.2020

  2020cites this paper
• LYMPHOMA: A BRIEF REVIEW OF ROLE OF IMAGING IN STAGING AND FOLLOW UP

  2020cites this paper
• Functional Imaging in Hodgkin Lymphoma

  2020cites this paper
• Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed Tomography Scans in the Management of Post-Transplant Lymphoproliferative Disease in Pediatric Patient.

  2020cites this paper
• Beyond lymph nodes: 18F-FDG PET/CT in detection of unusual sites of extranodal lymphoma

  2019cites this paper
• The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis

  2019cites this paper
• Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP

  2019cites this paper
• Increased 18F-FDG accumulation in the tonsils after chemotherapy for pediatric lymphoma: a common physiological phenomenon

  2019cites this paper
• Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma

  2019cites this paper
• Diffuse Large B-Cell Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up

  2019cites this paper
• The role of PET/CT in the modern treatment of Hodgkin lymphoma.

  2019cites this paper
• Tomographie par émission de positons dans les hémopathies lymphoïdes

  2019cites this paper
• Gastrointestinal Lymphomas

  2019cites this paper
• PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma.

  2019cites this paper
• 18F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural Networks.

  2019cites this paper
• Lymphomes

  2019cites this paper
• Hepatic infiltration helps predict outcome in dogs with multicentric large B cell lymphoma

  2019cites this paper
• Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas

  2019cites this paper
• Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma

  2019cites this paper
• Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume

  2019cites this paper
• Non-Hodgkin Lymphomas : Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes

  2019cites this paper
• Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas

  2019cites this paper
• UČESTALOST EPSTEIN-BARR VIRUS - POVEZANOG KLASIČNOG HODGKINOVOG LIMFOMA U KBC-u SPLIT U DESETOGODIŠNJEM RAZDOBLJU

  2019cites this paper
• Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas

  2018cites this paper
• Indications de la TEP-FDG en oncologie. Mise à jour selon les recommandations de prise en charge européennes et américaines

  2018cites this paper
• Hepatic Lymphoma: A Perplexing CT Diagnosis made Easy by 18F-FDG PET CT Imaging

  2018cites this paper
• PET/CT in Lymphoma: Current Overview and Future Directions.

  2018cites this paper
• Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.

  2018cites this paper
• Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group

  2018cites this paper
• [Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases].

  2018influential citation
• PET imaging for assessing tumor response to therapy

  2018cites this paper
• Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis

  2018cites this paper
• Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography

  2018cites this paper
• Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT.

  2018cites this paper
• R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

  2018cites this paper
• Enlightening the forgotten organ: PET-CT findings on thymic lesions

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Whole-body Mri versus 18 F-FDg PeT/cT for pretherapeutic assessment and staging of lymphoma: a meta-analysis

  2018cites this paper